BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36593626)

  • 41. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.
    Hamada N; Maeda A; Takase-Minegishi K; Kirino Y; Sugiyama Y; Namkoong H; Horita N; Yoshimi R; Nakajima H;
    Front Immunol; 2021; 12():803410. PubMed ID: 34938300
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cascade of immunologic adverse events related to pembrolizumab treatment.
    Dhenin A; Samartzi V; Lejeune S; Seront E
    BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31167767
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
    Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
    J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
    Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
    ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit.
    Deharo F; Carvelli J; Cautela J; Garcia M; Sarles C; Maues de Paula A; Bourenne J; Gainnier M; Bichon A
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233479
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody.
    Ono R; Iwai Y; Yamazaki T; Takahashi H; Hori Y; Fukushima K; Saotome T
    Intern Med; 2022 Oct; 61(19):2973-2979. PubMed ID: 35314545
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma.
    Lara MS; Afify A; Ellis MP; Phan CT; Richman DP; Riess JW
    Clin Lung Cancer; 2019 Jul; 20(4):e489-e491. PubMed ID: 31085042
    [No Abstract]   [Full Text] [Related]  

  • 48. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review.
    Cozma A; Sporis ND; Lazar AL; Buruiana A; Ganea AM; Malinescu TV; Berechet BM; Fodor A; Sitar-Taut AV; Vlad VC; Negrean V; Orasan OH
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142866
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pembrolizumab-induced myasthenia gravis: A fatal case report.
    March KL; Samarin MJ; Sodhi A; Owens RE
    J Oncol Pharm Pract; 2018 Mar; 24(2):146-149. PubMed ID: 28147928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune Checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade.
    Nelke C; Pawlitzki M; Kerkhoff R; Schroeter CB; Aktas O; Neuen-Jacob E; Polzin A; Meuth SG; Ruck T
    Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):. PubMed ID: 37884388
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune checkpoint inhibitor-associated myositis and myasthenia gravis overlap: Understanding the diversity in a case series.
    Wong EYT; Yong MH; Yong KP; Tan EH; Toh CK; Kanesvaran R; Takano A; Ng QS
    Asia Pac J Clin Oncol; 2021 Oct; 17(5):e262-e267. PubMed ID: 32985078
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.
    Moreira A; Loquai C; Pföhler C; Kähler KC; Knauss S; Heppt MV; Gutzmer R; Dimitriou F; Meier F; Mitzel-Rink H; Schuler G; Terheyden P; Thoms KM; Türk M; Dummer R; Zimmer L; Schröder R; Heinzerling L
    Eur J Cancer; 2019 Jan; 106():12-23. PubMed ID: 30453170
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature.
    Yin B; Xiao J; Wang X; Li X; Guan Y; Chen J; Han P; Li K; Wang J
    Front Med (Lausanne); 2022; 9():950801. PubMed ID: 36457566
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fatal myasthenia gravis (MG) associated with myositis and myocarditis in a patient with pre-existing MG treated by adjuvant nivolumab for a stage III melanoma.
    Emile J; Cauquil C; Carpentier D; Routier E; Robert C
    Eur J Cancer; 2024 Jul; 205():114098. PubMed ID: 38761774
    [No Abstract]   [Full Text] [Related]  

  • 56. Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis.
    Cautela J; Zeriouh S; Gaubert M; Bonello L; Laine M; Peyrol M; Paganelli F; Lalevee N; Barlesi F; Thuny F
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298621
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians.
    Raschi E; Rossi S; De Giglio A; Fusaroli M; Burgazzi F; Rinaldi R; Potena L
    Drug Saf; 2023 Sep; 46(9):819-833. PubMed ID: 37341925
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
    Rossi S; Gelsomino F; Rinaldi R; Muccioli L; Comito F; Di Federico A; De Giglio A; Lamberti G; Andrini E; Mollica V; D'Angelo R; Baccari F; Zenesini C; Madia P; Raschi E; Cortelli P; Ardizzoni A; Guarino M
    J Neurol; 2023 Jun; 270(6):2975-2986. PubMed ID: 36800019
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
    Jespersen MS; Fanø S; Stenør C; Møller AK
    Eur Heart J Case Rep; 2021 Nov; 5(11):ytab342. PubMed ID: 34870082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Myasthenia Gravis and Myocarditis After Administration of Pembrolizumab in a Patient With Metastatic Non-small Cell Lung Cancer and Resected Thymoma.
    Kee W; Ng KYY; Lee JJX; Tan DSW
    Clin Lung Cancer; 2022 Jun; 23(4):e293-e295. PubMed ID: 35105525
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.